TORONTO and HAIFA, Israel, May 02, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is deepening its engagement with the European financial and healthcare communities through participation in three upcoming events. This increased activity follows NurExone’s recent announcement of a potential third therapeutic indication for its lead drug asset, ExoPTEN – underscoring the Company’s momentum and expansion within the biotechnology sector.
CEO Dr. Lior Shaltiel will represent NurExone at INVEST 2025 in Stuttgart, a leading investment conference for German-speaking markets including Germany, Austria, and Switzerland. The conference provides a platform for NurExone to present its corporate strategy, pipeline development, and the latest progress with ExoPTEN to an influential audience of institutional and private investors. The initiative is being actively supported by Dr. Eva Reuter, who leads NurExone’s investor relations efforts in Germany.